Brokers have been very busy this month recommending which ASX 200 shares to buy, hold, and sell.
Three which analysts have given their verdict on are named below. Here's what they are saying about them:
Image source: Getty Images
Beach Energy Ltd (ASX: BPT)
This energy producer's shares are fully valued according to analysts at Morgans. Given its free cash flow outlook and difficult to analyse results, the broker has downgraded Beach Energy shares from a hold rating to a trim rating with a $1.09 price target. This compares to its current share price of $1.13. It said:
A noisy 1H26 result that was hard to analyse, with the treatment of various items not aligning with what we would expect. Pushing its accounting treatments harder than its operations leaves us concerned around BPT's forward FCF profile. Gradually declining reserves could suppress BPT's valuation until it makes an acquisition, a difficult position to be in. We downgrade our rating to TRIM (from HOLD), with an updated A$1.09 target price.
CSL Ltd (ASX: CSL)
The team at Bell Potter hasn't been overly impressed with recent developments at this biotechnology giant. So, although CSL shares trade at a sizeable discount to historical earnings multiples, it only rates them as a hold with a $175.00 price target. This compares to its current share price of $163.44.
Commenting on the struggling company, the broker said:
CSL now trades on an underlying PE of 16.5x in FY27, well below its historical average but remains above the global biopharma avg of ~15x. It faces the daunting prospect of hiring a new CEO to re-invigorate a lacklustre growth outlook in the face of headwinds on multiple fronts.
Pro Medicus Ltd (ASX: PME)
Morgans is feeling upbeat about this ASX tech stock ahead of the release of its results. In response to the AI-induced software selloff, the broker has upgraded Pro Medicus shares to a buy rating with a $290.00 price target. This implies more than 70% upside for investors from its current share price of $169.47. It said:
PME has been sold off heavily as investors increasingly worry that AI could structurally erode the economics and commoditise premium imaging SaaS platforms. For PME, that feels misunderstood. Bravery required with volatility high and trend weak, but this has proven to be a good time to pick up PME shares. Upgrade to BUY on weakness. 1H26 results due 12th of February.
